文献速递瓣膜病与结构性心脏病

生物瓣主动脉瓣亚临床瓣叶血栓影响运动的自然史

Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves.
PubMed 文献 · Eur Heart J · 2017-01-01

SAVORY注册研究纳入TAVI(75例)或SAVR(30例)后两次4DCT可评估且抗栓治疗未变的患者,分析HALT和HAM的演变。84例分析人群中,HALT见于38.1%,HAM见于20.2%,二者动态变化,进展15.5%、消退10.7%。与抗血小板治疗相比,口服抗凝治疗者进展可能性更低(OR 0.014,P=0.036),但慢性口服抗凝并非消退的显著预测因素。

要点

  • TAVI和SAVR后亚临床瓣叶血栓常见,HALT 38.1%、HAM 20.2%。
  • HALT和HAM可进展或消退,进展15.5%、消退10.7%。
  • 口服抗凝治疗可能减少HALT进展,但不显著预测消退。

核心结论

  • 亚临床瓣叶血栓是TAVI和SAVR后的常见发现,可从正常瓣叶进展为HALT再至更严重的HAM,也可在不同时间间隔消退。
  • 抗凝药可能对HALT发生产生保护作用,但HALT也可在无抗凝治疗时消退。

研究设计与样本

  • SAVORY注册研究(NCT02426307)纳入TAVI(n=75)或SAVR(n=30)后两次4DCT均可完整评估HALT和HAM且两次扫描间抗栓药物未变的患者。
  • 分析人群84例,第一次和第二次CT分别在瓣膜植入后140±152天和298±141天进行。
  • 采用逻辑回归分析HALT和HAM的演变,校正人口学和基线变量、两次CT时间、瓣膜类型和抗栓治疗。

主要发现

  • HALT见于32例(38.1%),其中HAM见于17例(20.2%)。
  • HALT和HAM均为动态变化,进展见于13例(15.5%),消退见于9例(10.7%)。
  • 与抗血小板治疗相比,口服抗凝药(维生素K拮抗剂或非VKA口服抗凝药)患者进展可能性更低(OR 0.014,P=0.036)。
  • 长期口服抗凝治疗并非消退的显著预测因素。
  • 上述发现在经导管和外科生物瓣主动脉瓣中相似;无患者出现瓣膜功能障碍症状,瓣叶增厚与任何临床事件无明确关联。

临床怎么用

  • TAVI或SAVR后应关注亚临床瓣叶血栓(HALT/HAM)的动态变化,其可进展或消退。
  • 口服抗凝治疗可能降低HALT进展风险,但HALT也可无抗凝治疗时消退,需个体化评估抗栓策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Four-dimensional volume-rendered computed tomography (4DCT) has demonstrated instances of hypo-attenuating leaflet thickening (HALT) with or without hypo-attenuation affecting motion (HAM) after transcatheter and surgical aortic valve implantation (TAVI, SAVR). The temporal pattern of evolution of these phenomena is uncertain. METHODS AND RESULTS: The SAVORY registry enrolled patients treated by TAVI (n = 75) or SAVR (n = 30) with two 4DCT scans fully interpretable for HALT and HAM as well as unchanged anti-thrombotic medication between the scans. Logistic regression analysis was performed to examine the evolution of HALT and HAM while accounting for demographic and baseline variables, timing of both CT scans, valve type and antithrombotic therapy. The analysis population consisted of 84 patients, in whom first and second CT scans were performed at 140 ± 152 days and 298 ± 141 days after valve implantation, respectively. Hypo-attenuating leaflet thickening was noted in 32 patients (38.1%), with HAM in 17 (20.2%). Both findings were dynamic, showing progression in 13 (15.5%) and regression and 9 (10.7%) patients. Compared with antiplatelet therapy, progression was less likely among patients on oral anticoagulation with vitamin-K antagonists or non-VKA oral anticoagulants (odds ratio: 0.014, P = 0.036). Maintenance on chronic oral anticoagulation was not a significant predictor of regression. These findings were similar for both transcatheter and surgical bioprosthetic aortic valves. No patients developed symptoms of valve dysfunction and leaflet thickening was not clearly associated with any clinical events. CONCLUSIONS: Subclinical leaflet thrombosis is a common finding after TAVI and SAVR, and may progress from normal leaflet over HALT to the more severe HAM. The phenomenon can develop and regress at variable intervals after valve implantation. Anticoagulants may have a protective effect against the development of HALT, but HALT can also regress without anticoagulation therapy. REGISTERED AT CLINICALTRIALS.GOV: NCT02426307.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Sondergaard L, De Backer O, Kofoed KF, et al. Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves. Eur Heart J. 2017. PMID: 28838044. doi:10.1093/eurheartj/ehx369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。